Network pharmacology and molecular docking showed that GQZ can effectively treat NSCLC by inhibiting the PI3K/AKT1 signaling pathway, inhibiting cell proliferation through C-MYC and PCNA, and promoting apoptosis through the intrinsic pathway. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.